4 recruiting, 2 terminated, 1 completed, 1 unknown. 4 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Terminated 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow CNS Metastases: new trials by email Literature Review of CNS Metastases trials Research Report on CNS Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) 25 mCi 177Lu- DTPA-omburtamab - Recurrent Medulloblastoma, Refractory Medulloblastoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-07-02 | 2026-10-08 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Samsung Medical Center | 37 | 2024-05-01 | 2026-04-23 |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers IAM1363 - HER2 Mutation-Related Tumors, HER2 | Phase 1 | Recruiting | Iambic Therapeutics, Inc | 383 | 2024-03-25 | 2026-09-09 |
| An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis Furmonertinib - EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases | Unknown | Tang-Du Hospital | 30 | 2022-01-28 | 2024-04-08 | |
| A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours Samples collection: Plasma, Samples collection: CSF, Samples collection: Non-CNS Metastatic Tumour Tissue - CNS Metastases | Not applicable | Recruiting | Jules Bordet Institute | 600 | 2020-07-01 | 2026-01-06 |
| 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases 131I-omburtamab - Neuroblastoma, CNS Metastases | Phase 2 / Phase 3 | Terminated | Y-mAbs Therapeutics | 52 | 2018-12-11 | 2024-02-13 |
| Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls Metastatic Melanoma, CNS Metastases | Withdrawn | University of Pittsburgh | 2012-07-01 | 2016-07-27 | ||
| Electrochemotherapy as a Palliative Treatment for Brain Metastases The Electroporation System, Bleomycin - Brain Metastases, CNS Metastases | Phase 1 | Terminated | Copenhagen University Hospital at Herlev | 1 | 2011-04-01 | 2013-07-31 |
Brain Neoplasms (3) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Medulloblastoma (1) · Melanoma (1) · Meningeal Carcinomatosis (1) · Meningioma (1) · Multiple Sclerosis (1) · Neoplasm Metastasis (1) · Neurilemmoma (1) · Neuroblastoma (1) · Neurofibroma (1)
Neoplasms by Site (5) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neuroectodermal Tumors (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Central Nervous System Neoplasms (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Neuroepithelial (3) · Meningeal Neoplasms (2) · Neuroectodermal Tumors, Primitive (2)
Bleomycin (1) · Blood Specimen Collection (1) · Carboplatin (1) · Dexamethasone (1) · Etoposide (1) · Ifosfamide (1) · Mn-PyC3A (1) · aflutinib (1) · omburtamab I-131 (1) · selinexor (1)
Copenhagen University Hospital at Herlev (1) · Iambic Therapeutics, Inc (1) · Jules Bordet Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Reveal Pharmaceuticals Inc. (1) · Samsung Medical Center (1) · Tang-Du Hospital (1) · University of Pittsburgh (1) · Y-mAbs Therapeutics (1)
United States (4) · Denmark (2) · France (2) · South Korea (2) · Spain (2) · Belgium (1) · China (1) · Ireland (1) · Italy (1) · Japan (1) · Luxembourg (1) · Netherlands (1) · United Kingdom (1)
Haichuan Su, PhD (1) · John Roemer, MD (1) · Julie Gehl, MD, DMSci (1) · Nuria Kotecki, MD (1) · Sameer Farouk Sait, MBBS (1) · Seok Jin Kim (1) · Stergios Moschos, MD (1)
PMID 38464207, PMID 39083105, PMID 42835688
R44CA261240 (1)